MAVENIR
4.4.2022 09:02:11 CEST | Business Wire | Press release
Vodafone Portugal, a leading telecom provider in Portugal, and Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Vodafone Portugal will be using the MAVcore solution for its fully containerised Converged Packet Core network after the selection of Mavenir as strategic 5G Converged Core supplier.
The MAVcore family includes Mavenir’s leading-edge Converged Packet Core and Policy Control solution delivering a next-generation modernised data network. The MAVcore solution will allow the transformation to a containerised and automated cloud-native network – providing the flexibility for future mobile network evolution, including the launch of disruptive and innovative 5G Stand Alone applications for Vodafone customers in Portugal.
The 5G Converged Packet Core solution is designed with cloud-native containerised techniques providing a fully scalable and virtualised network architecture. The solution uses software running on commercial off-the-shelf (COTS) hardware that provides cost-effectiveness, flexibility, and agility. Mavenir Converged Packet Core with multi-access support (2G, 3G, 4G, 5G) allows Communication Service Providers (CSPs) like Vodafone to plan for future growth and a greater focus on security and reliability. It simplifies network transformation and enables operational efficiencies with complete automation.
Paulino Correa, Network Director, Vodafone Portugal, said; “The industry defines several steps for 5G – the first one was launched back in November – but it is the second step, the 5G Stand Alone Core, that brings the more powerful technology revolution in terms of use cases. For our strategic 5G Stand Alone Core supplier, we wanted a vendor who would have innovation at its heart and equally provide us with a technically leading converged Packet Core solution. We have been working on 5G SA with Mavenir in our lab for over 1 year and are now ready to deliver a cloud-native Packet Core platform that will transform our network and prepare it for powerful applications and differentiating use cases, as the 5G solution evolves.”
Stefano Cantarelli, Chief Marketing Officer, Mavenir, said; “Mavenir has been working with Vodafone Group across various projects and we are delighted to now be part of their next-generation Converged Packet Core network under the Spring 3 Cosmos programme – we look forward to transforming Vodafone Portugal’s existing network into a dynamic, agile, fully automated for simplified operation and cloud-native based platform.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vodafone Portugal:
Vodafone Portugal is part of the Vodafone Group which is a leading technology communications company. Vodafone is the largest mobile and fixed network operator in Europe and a leading global IoT connectivity provider. Vodafone Group operates mobile and fixed networks in 21 countries and partner with mobile networks in 48 more. Vodafone Portugal currently serves 3.6 million homes and businesses with its next generation network and has over 4.6 million mobile customers.
https://www.vodafone.pt/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
